share_log

As Part Of Wave Life Sciences' Ongoing Collaboration With GSK, GSK Has Selected Its First Two Oligonucleotide Programs, GSK Will Provide An Initiation Payment Of $12M

ウェーブライフサイエンシズとGSKの持続的な協力の一環として、GSKは最初の2つのオリゴヌクレオチドプログラムを選択し、GSKは12百万ドルの開始支払いを提供します。

Benzinga ·  04/23 10:22
  • GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNAc-siRNA format with potential for best-in-class potency and durability
  • GSK collaboration continues to span all Wave modalities, including RNA editing, with target validation ongoing in multiple therapy areas
  • Wave is on track to initiate a clinical trial of its wholly owned INHBE program for obesity in 1Q 2025, which also uses the company's next generation siRNA
これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする